Why I like to invest in a category leader in allogeneic CART – Allogene (feat. management team, TPG, Pfizer, and Gilead)
Improvement in genomic analysis is fueling increased understanding of disease pathology, and simultaneous improvement in gene editing technologies are having massive synergies in development of new breakthrough therapeutics - with…